Celso Dario Ramos

Prof. Dr. Celso Dario Ramos

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NTNatália Tobar
Natália Tobar
GRGuilherme Rocha
Guilherme Rocha
ASAndrey Santos
Andrey Santos
DGDioze Guadagnini
Dioze Guadagnini
HAHeloisa Balan Assalin
Heloisa Balan Assalin
MSMario J. A. Saad
Mario J. A. Saad
Metformin is the most prescribed drug for DM2, but its site and mechanism of action are still not well established. Here, we investigated the effects of metformin on basolateral intestinal glucose uptake (BIGU), and its consequences on hepatic glucose production (HGP). In diabetic patients and mice, the primary site of metformin action was the gut, increasing BIGU, evaluated through PET-CT. In mice and CaCo2 cells, this increase in BIGU resulted from an increase in GLUT1 and GLUT2, secondary to ATF4 and AMPK. In hyperglycemia, metformin increased the lactate (reducing pH and bicarbonate in portal vein) and acetate production in the gut, modulating liver pyruvate carboxylase, MPC1/2, and FBP1, establishing a gut-liver crosstalk that reduces HGP. In normoglycemia, metformin-induced increases in BIGU is accompanied by hypoglycemia in the portal vein, generating a counter-regulatory mechanism that avoids reductions or even increases HGP. In summary, metformin increases BIGU and through gut-liver crosstalk influences HGP.

4 August 2012 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
DBDaniel C. Bortot
Daniel C. Bortot
BABárbara J. Amorim
Bárbara J. Amorim
GOGlaucia C. Oki
Glaucia C. Oki
SGSérgio B. Gapski
Sérgio B. Gapski
ASAllan O. Santos
Allan O. Santos
CRCelso Dario Ramos
Celso Dario Ramos

16 February 2022 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
IBIvan Luiz Padilha Bonfante
Ivan Luiz Padilha Bonfante
MMMilena Monfort-Pires
Milena Monfort-Pires
RDRenata Duft
Renata Duft
KMKeryma Chaves da Silva Mateus
Keryma Chaves da Silva Mateus
JJJosé Carlos de Lima Júnior
José Carlos de Lima Júnior
CCCláudia Regina Cavaglieri
Cláudia Regina Cavaglieri

11 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MTMaria Emilia Seren Takahashi
Maria Emilia Seren Takahashi
CMCamila Mosci
Camila Mosci
ESEdna M. Souza
Edna M. Souza
SBSérgio Q. Brunetto
Sérgio Q. Brunetto
EEElba Etchebehere
Elba Etchebehere
CRCelso Dario Ramos
Celso Dario Ramos
Many efforts have been made to standardize the interpretation of 18F-FDG PET/CT in multiple myeloma (MM) with qualitative visual analysis or with quantitative metabolic parameters using various methods for lesion segmentation of PET images. The aim of this study was to propose a quantitative method for bone and bone marrow evaluation of 18F-FDG PET/CT considering the extent and intensity of bone 18F-FDG uptake: Intensity of Bone Involvement (IBI). Whole body 18F-FDG PET/CT of 59 consecutive MM patients were evaluated. Compact bone tissue was segmented in PET images using a global threshold for HU of the registered CT image. A whole skeleton mask was created and the percentage of its volume with 18F-FDG uptake above hepatic uptake was calculated (Percentage of Bone Involvement - PBI). IBI was defined by multiplying PBI by mean SUV above hepatic uptake. IBI was compared with visual analysis performed by two experienced nuclear medicine physicians. IBI calculation was feasible in all images (range:0.00–1.35). Visual analysis categorized PET exams into three groups (negative/mild, moderate and marked bone involvement), that had different ranges of IBI (multi comparison analysis, p < 0.0001). There was an inverse correlation between the patients’ hemoglobin values and IBI (r = −0.248;p = 0.02). IBI score is an objective measure of bone and bone marrow involvement in MM, allowing the categorization of patients in different degrees of aggressiveness of the bone disease. The next step is to validate IBI in a larger group of patients, before and after treatment and in a multicentre setting.

24 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LMLudmilla Moura
Ludmilla Moura
Lígia Nunes de Morais RibeiroLígia Nunes de Morais Ribeiro
Lígia Nunes de Morais Ribeiro
FCFabíola Vieira de Carvalho
Fabíola Vieira de Carvalho
GSGustavo Rodrigues da Silva
Gustavo Rodrigues da Silva
PFPriscila C. Lima Fernandes
Priscila C. Lima Fernandes
Eneida De PaulaEneida De Paula
Eneida De Paula
Melanoma is the most aggressive skin carcinoma and nanotechnology can bring new options for its pharmacological treatment. Nanostructured lipid carriers (NLC) are ideal drug-delivery carriers for hydrophobic drugs, such as the antineoplastic docetaxel (DTX), and hybrid (NLC-in-hydrogel) systems are suitable for topical application. This work describes a formulation of NLCDTX in xanthan-chitosan hydrogel containing lidocaine (LDC) with anticancer and analgesia effects. The optimized nanoparticles encapsulated 96% DTX and rheological analysis revealed inherent viscoelastic properties of the hydrogel. In vitro assays over murine fibroblasts (NIH/3T3) and melanoma cells (B16-F10), human keratinocytes (HaCaT) and melanoma cells (SK-MEL-103) showed reduction of docetaxel cytotoxicity after encapsulation in NLCDTX and HGel-NLCDTX. Addition of LDC to the hybrid system (HGel-NLCDTX-LDC) increased cell death in tumor and normal cells. In vivo tests on C57BL/6J mice with B16-F10-induced melanoma indicated that LDC, NLCDTX, HGel-NLCDTX-LDC and NLCDTX + HGel-LDC significantly inhibited tumor growth while microPET/SPECT/CT data suggest better prognosis with the hybrid treatment. No adverse effects were observed in cell survival, weight/feed-consumption or serum biochemical markers (ALT, AST, creatinine, urea) of animals treated with NLCDTX or the hybrid system. These results confirm the adjuvant antitumor effect of lidocaine and endorse HGel-NLCDTX-LDC as a promising formulation for the topical treatment of melanoma.

27 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EPEder C. Pincinato
Eder C. Pincinato
ECEricka F. D. Costa
Ericka F. D. Costa
LLLeisa Lopes-Aguiar
Leisa Lopes-Aguiar
GNGuilherme A. S. Nogueira
Guilherme A. S. Nogueira
TLTathiane R. P. Lima
Tathiane R. P. Lima
CLCarmen Silvia Passos Lima
Carmen Silvia Passos Lima
Cisplatin (CDDP) combined with radiotherapy (RT) is employed in head and neck squamous cell carcinoma (HNSCC) with variable toxicities and clinical response. Glutathione S-transferases (GSTs) participate in CDDP excretion from cells, and genes encoding GSTs,GSTM1,GSTT1andGSTP1, are polymorphic in humans. This prospective study aimed to evaluate the roles ofGSTM1,GSTT1, andGSTP1Ile105Val polymorphisms in outcomes of HNSCC patients treated with CDDP chemoradiation. Ninety patients were genotyped by multiplex PCR. Urinary CDDP measurements were performed by HPLC. Treatment side effects and response were analysed by conventional criteria. Patients withGSTT1genes showed 7.23- and 5.37-fold higher likelihood of presenting vomiting and ototoxicity, lower glomerular filtration rate (GFR), and lower elimination of CDDP in urine relative to patients with deleted genes. Patients harbouring theGSTP1IleVal or ValVal genotypes showed 4.28-fold higher likelihood of presenting grade 2 or 3 vomiting and lower GFR with treatment than those harbouring the IleIle genotype. In multivariate Cox analysis, patients with theGSTP1105ValVal genotype had 3.87 more chance of presenting disease progression than those with the IleIle or IleVal genotype (p < 0.01). Our findings provide preliminary evidence that inherited abnormalities in CDDP metabolism, related toGSTT1andGSTP1Ile105Val polymorphisms, alter outcomes of HNSCC patients treated with CDDP and RT.